Dr. Patel on the FDA Approval of Durvalumab in NSCLC

In Partnership With:

Partner | Cancer Centers | <b>University of Chicago Medicine Comprehensive Cancer Center</b>

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non—small cell lung cancer (NSCLC).